“Diabetes continues to be our core area in India”

For Lilly, a company whose history in insulin production dates to 1923, caring for diabetes patients in India is clearly a priority. In an exclusive interview with the BioSpectrum, Mr Edgard Olaizola, managing director, Eli Lilly India gave insights into

lilly

What is your primary area of focus currently? Please tell us about the achievements of Eli Lilly in last one year?

Our focus has been mainly on diabetes, oncology and osteoporosis. Diabetes continues to be our core area as its product portfolio brings 70 percent of revenues to the company. We are committed to making life better for people living with diabetes and have been working to meet the needs of people with diabetes beyond medicines as well.

We launched a insulin delivery Eli Lilly is planning to launch new medication formulation for diabetes by this year end (2015). Besides that, we are also working on an oncology medicine and hope to launch it by late next year (2016) or early following year (2017).

Overall our revenues are growing in double digit. We are pleased with the performance of our portfolio. The insulin and analogs have been key business accelerators. We have been grown by more than 20 percent in the last fiscal and expect that to continue in the coming time with introduction of newer products over the period of time.

Is market is performing as per your expectations?

 

Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X